Show simple item record

dc.contributor.authorCirenajwis, Helenaen_US
dc.contributor.authorEkedahl, Henriken_US
dc.contributor.authorLauss, Martinen_US
dc.contributor.authorHarbst, Katjaen_US
dc.contributor.authorCarneiro, Anaen_US
dc.contributor.authorEnoksson, Jensen_US
dc.contributor.authorRosengren, Fridaen_US
dc.contributor.authorWerner-Hartman, Lindaen_US
dc.contributor.authorTörngren, Thereseen_US
dc.contributor.authorKvist, Andersen_US
dc.contributor.authorFredlund, Eriken_US
dc.contributor.authorBendahl, Pär-Olaen_US
dc.contributor.authorJirström, Karinen_US
dc.contributor.authorLundgren, Lottaen_US
dc.contributor.authorHowlin, Jillianen_US
dc.contributor.authorBorg, Åkeen_US
dc.contributor.authorGruvberger-Saal, Sofia K.en_US
dc.contributor.authorSaal, Lao H.en_US
dc.contributor.authorNielsen, Karien_US
dc.contributor.authorRingnér, Markusen_US
dc.contributor.authorTsao, Hensinen_US
dc.contributor.authorOlsson, Håkanen_US
dc.contributor.authorIngvar, Christianen_US
dc.contributor.authorStaaf, Johanen_US
dc.contributor.authorJönsson, Göranen_US
dc.date.accessioned2015-08-03T14:02:29Z
dc.date.issued2015en_US
dc.identifier.citationCirenajwis, H., H. Ekedahl, M. Lauss, K. Harbst, A. Carneiro, J. Enoksson, F. Rosengren, et al. 2015. “Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy.” Oncotarget 6 (14): 12297-12309.en
dc.identifier.issn1949-2553en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:17820895
dc.description.abstractMelanoma is currently divided on a genetic level according to mutational status. However, this classification does not optimally predict prognosis. In prior studies, we have defined gene expression phenotypes (high-immune, pigmentation, proliferative and normal-like), which are predictive of survival outcome as well as informative of biology. Herein, we employed a population-based metastatic melanoma cohort and external cohorts to determine the prognostic and predictive significance of the gene expression phenotypes. We performed expression profiling on 214 cutaneous melanoma tumors and found an increased risk of developing distant metastases in the pigmentation (HR, 1.9; 95% CI, 1.05-3.28; P=0.03) and proliferative (HR, 2.8; 95% CI, 1.43-5.57; P=0.003) groups as compared to the high-immune response group. Further genetic characterization of melanomas using targeted deep-sequencing revealed similar mutational patterns across these phenotypes. We also used publicly available expression profiling data from melanoma patients treated with targeted or vaccine therapy in order to determine if our signatures predicted therapeutic response. In patients receiving targeted therapy, melanomas resistant to targeted therapy were enriched in the MITF-low proliferative subtype as compared to pre-treatment biopsies (P=0.02). In summary, the melanoma gene expression phenotypes are highly predictive of survival outcome and can further help to discriminate patients responding to targeted therapy.en
dc.language.isoen_USen
dc.publisherImpact Journals LLCen
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494939/pdf/en
dash.licenseLAAen_US
dc.subjectgene expressionen
dc.subjectmelanomaen
dc.subjectBRAFen
dc.subjectBRAF inhibitoren
dc.subjectmutationen
dc.titleMolecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapyen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalOncotargeten
dash.depositing.authorTsao, Hensinen_US
dc.date.available2015-08-03T14:02:29Z
dash.authorsorderedfalse
dash.contributor.affiliatedTsao, Hensin


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record